semaglutide cardiovascular outcomes 2025 news oral indication in High-Risk Type 2 Diabetes: Benefit Confirmed in the SOUL Trial ACC 2025: Oral Semaglutide Reduces – GLP-1 Studies Add to Growing

The benefits in ASCVD risk reduction with GLP-1RA are evidenced by 14% risk reduction in cardiovascular mortality with an NNTB of 207 to prevent one event, 13% MACE reduction with an NNT of 67 to prevent one event and 12% risk reduction in stroke with an NNT of 335 to prevent one event, along with their favourable safety profile of 6% increased overall adverse events

If no medication is prescribed after evaluation, Ro says the initial payment is refunded

However, whilst there is no official contraindication to taking these medications together, it is important to consider the practical implications

Quiazon CCL, Shomali ME

By understanding these differences, you can make smart decisions for your body and prepare accordingly